Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
verdinexor
- Development stage
- Preclinical
- Lead developer
- Karyopharm Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Verdinexor is a small molecule, orally bioavailable selective inhibitor of nuclear export (SINE) developed primarily for veterinary use. It acts by reversibly inhibiting the nuclear export protein Chromosome Region Maintenance 1 (CRM1), also known as Exportin 1 (XPO1). By blocking CRM1/XPO1, verdinexor prevents the export of tumor suppressor proteins and growth regulatory proteins from the nucleus, leading to their accumulation in the nucleus and reactivation of their anti-cancer functions. This results in selective induction of apoptosis in cancer cells while sparing healthy cells. Verdinexor is conditionally approved by the FDA as Laverdia-CA1 for oral treatment of lymphoma in dogs and has also demonstrated broad-spectrum antiviral activity in preclinical studies[3][5][6][8]. Developers: Karyopharm Therapeutics Manufacturers: Dechra
- Brand names
- Laverdia-CA1Laverdia-CA-1Laverdia-CA 1
- Other names
- verdinexor hydrochloride
02
Targets
XPO1 (Exportin-1)
Beyond the preview
Go deeper on verdinexor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on verdinexor.